$7.09
4.70% day before yesterday
NYSE, Nov 21, 10:20 pm CET
ISIN
US5019761049
Symbol
KYTX

Kyverna Therapeutics Stock price

$7.09
-0.05 0.70% 1M
+4.88 220.81% 6M
+3.35 89.57% YTD
+3.10 77.69% 1Y
-14.91 67.77% 3Y
-14.91 67.77% 5Y
-14.91 67.77% 10Y
-14.91 67.77% 20Y
NYSE, Closing price Fri, Nov 21 2025
-0.35 4.70%
ISIN
US5019761049
Symbol
KYTX
Industry

Key metrics

Basic
Market capitalization
$310.5m
Enterprise Value
$139.6m
Net debt
positive
Cash
$171.1m
Shares outstanding
43.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
2.0
Financial Health
Equity Ratio
87.5%
Return on Equity
-47.6%
ROCE
-111.9%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-169.6m | $-195.0m
EBIT
$-171.6m | $-188.9m
Net Income
$-161.0m | $-168.8m
Free Cash Flow
$-158.4m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-41.2% | -38.5%
EBIT
-40.5% | -32.1%
Net Income
-44.8% | -32.9%
Free Cash Flow
-62.0%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-3.7
FCF per Share
$-3.6
Short interest
10.9%
Employees
129
Rev per Employee
$0.0
Show more

Is Kyverna Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,049 stocks worldwide.

Kyverna Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Kyverna Therapeutics forecast:

11x Buy
92%
1x Hold
8%

Analyst Opinions

12 Analysts have issued a Kyverna Therapeutics forecast:

Buy
92%
Hold
8%

Financial data from Kyverna Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 34 34
28% 28%
-
- Research and Development Expense 137 137
43% 43%
-
-170 -170
41% 41%
-
- Depreciation and Amortization 1.99 1.99
2% 2%
-
EBIT (Operating Income) EBIT -172 -172
40% 40%
-
Net Profit -161 -161
45% 45%
-

In millions USD.

Don't miss a Thing! We will send you all news about Kyverna Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Kyverna Therapeutics Stock News

Positive
Seeking Alpha
9 days ago
Kyverna Therapeutics receives a strong buy rating with a $55 price target, driven by revolutionary Phase 2 data for KYV-101 in myasthenia gravis. KYV-101 demonstrated double the efficacy of standard care and enabled 100% of patients to achieve drug-free remission, with a best-in-class safety profile. The platform is significantly de-risked, with experienced management, strong financials, and cl...
Neutral
GlobeNewsWire
11 days ago
Topline data from registrational trial in stiff person syndrome (SPS) now expected in early 2026; narrowed from previous guidance of first half 2026; BLA submission anticipated in 1H 2026
Neutral
GlobeNewsWire
13 days ago
EMERYVILLE, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that Warner Biddle, Chief Executive Officer of Kyverna, will present at the Jefferies Global Healthcare Conference in London, United Kingdom on Monday, Nove...
More Kyverna Therapeutics News

Company Profile

Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company. It develops treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.

Head office United States
CEO Warner Biddle
Employees 129
Founded 2018
Website kyvernatx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today